

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

APC/Fire(TM) 750 anti-human CD4

RRID:AB_2629693

Type: Antibody

Proper Citation

BioLegend Cat# 300560, RRID:AB_2629693

Antibody Information

URL: http://antibodyregistry.org/AB_2629693

Proper Citation: BioLegend Cat# 300560, RRID:AB_2629693

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Fire(TM) 750 anti-human CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone RPA-T4

Antibody ID: AB_2629693

Vendor: BioLegend

Catalog Number: 300560

Alternative Catalog Numbers: 300559

Record Creation Time: 20231110T034745+0000

Record Last Update: 20260829T041834+0000

Ratings and Alerts

No rating or validation information has been found for APC/Fire(TM) 750 anti-human CD4.

No alerts have been found for APC/Fire(TM) 750 anti-human CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hegab Souquette A, et al. (2026) Integrated drivers of basal and acute immunity in diverse human populations. Cell reports. Medicine, 7(4), 102690.

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. The Journal of pharmacology and experimental therapeutics, 392(8), 103634.

Petrov L, et al. (2025) Rewired type I IFN signaling is linked to age-dependent differences in COVID-19. Cell reports. Medicine, 6(8), 102285.

Hegelmaier T, et al. (2025) Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis. Med (New York, N.Y.), 6(9), 100776.

Vanshylla K, et al. (2022) Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell host & microbe, 30(1), 69.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 185(3), 493.